|
FDA to Be Flexible With Trials for Rare Disease Treatments
The FDA is prepared to apply flexibility to the review of products that tackle rare diseases, according to the agency’s chief scientist.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives